Zoetis Inc. (NYSE:ZTS) Announces Quarterly Dividend of $0.33

Zoetis Inc. (NYSE:ZTSGet Rating) announced a quarterly dividend on Thursday, May 19th, Zacks reports. Shareholders of record on Thursday, July 21st will be given a dividend of 0.325 per share on Thursday, September 1st. This represents a $1.30 annualized dividend and a dividend yield of 0.80%. The ex-dividend date is Wednesday, July 20th.

Zoetis has a payout ratio of 22.0% meaning its dividend is sufficiently covered by earnings. Equities research analysts expect Zoetis to earn $5.79 per share next year, which means the company should continue to be able to cover its $0.80 annual dividend with an expected future payout ratio of 13.8%.

ZTS stock opened at $162.56 on Friday. The firm has a market cap of $76.51 billion, a price-to-earnings ratio of 37.28, a PEG ratio of 2.66 and a beta of 0.77. The firm has a 50-day simple moving average of $182.03 and a two-hundred day simple moving average of $201.77. Zoetis has a one year low of $156.67 and a one year high of $249.27. The company has a debt-to-equity ratio of 1.12, a quick ratio of 1.58 and a current ratio of 2.25.

Zoetis (NYSE:ZTSGet Rating) last released its quarterly earnings results on Thursday, May 5th. The company reported $1.32 EPS for the quarter, beating the consensus estimate of $1.23 by $0.09. The business had revenue of $2 billion during the quarter, compared to analyst estimates of $1.98 billion. Zoetis had a net margin of 26.27% and a return on equity of 49.62%. The company’s quarterly revenue was up 6.9% on a year-over-year basis. During the same period in the prior year, the firm posted $1.26 earnings per share. As a group, equities analysts predict that Zoetis will post 5.06 earnings per share for the current fiscal year.

ZTS has been the topic of several recent analyst reports. StockNews.com downgraded shares of Zoetis from a “strong-buy” rating to a “buy” rating in a report on Tuesday, April 26th. Citigroup cut their price objective on shares of Zoetis from $232.00 to $208.00 and set a “neutral” rating on the stock in a report on Wednesday, March 9th. Finally, The Goldman Sachs Group cut their price objective on shares of Zoetis from $237.00 to $208.00 and set a “buy” rating on the stock in a report on Thursday. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $231.88.

In other news, CEO Kristin C. Peck sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, February 25th. The shares were sold at an average price of $192.29, for a total transaction of $1,922,900.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Glenn David sold 32,390 shares of the firm’s stock in a transaction that occurred on Wednesday, February 23rd. The stock was sold at an average price of $189.87, for a total transaction of $6,149,889.30. The disclosure for this sale can be found here. In the last quarter, insiders sold 50,557 shares of company stock worth $9,589,496. 0.12% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently modified their holdings of the company. Worth Asset Management LLC acquired a new stake in shares of Zoetis during the 1st quarter worth approximately $26,000. Nelson Van Denburg & Campbell Wealth Management Group LLC grew its stake in shares of Zoetis by 430.8% during the 1st quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 138 shares of the company’s stock worth $26,000 after purchasing an additional 112 shares during the period. EverSource Wealth Advisors LLC acquired a new stake in shares of Zoetis during the 4th quarter worth approximately $50,000. Fairfield Bush & CO. acquired a new stake in shares of Zoetis during the 1st quarter worth approximately $134,000. Finally, Covestor Ltd grew its stake in shares of Zoetis by 102.8% during the 1st quarter. Covestor Ltd now owns 724 shares of the company’s stock worth $137,000 after purchasing an additional 367 shares during the period. 90.73% of the stock is currently owned by institutional investors and hedge funds.

About Zoetis (Get Rating)

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Further Reading

Dividend History for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.